Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
--Firdapse® NDA to be Resubmitted Before the End of this Quarter --Significant Progress with MuSK-MG Regulatory and Clinical Program --$84M Year-End Cash and Investments --Company to Host Quarterly...
-
CORAL GABLES, Fla., March 12, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for...
-
CORAL GABLES, Fla., March 08, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for...
-
CORAL GABLES, Fla., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for...
-
Positive meeting with the FDA about the resubmission of an NDA for FirdapseResubmission of NDA for Firdapse on schedule for end of the first quarter CORAL GABLES, Fla., Feb. 12, 2018 (GLOBE...
-
CORAL GABLES, Fla., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative...
-
CORAL GABLES, Fla., Nov. 30, 2017 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX) today reported that it has closed its previously announced public offering of shares of its common...
-
CORAL GABLES, Fla., Nov. 27, 2017 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (NasdaqCM:CPRX) announced today that it has commenced an underwritten public offering of 11 million shares of its...
-
-- Treatment with Firdapse Achieved Statistical Significance for Co-Primary Endpoints and Secondary Endpoint -- -- Positive Results to Support Planned NDA Submission in the First Quarter of 2018 -- ...
-
CORAL GABLES, Fla., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for...